Mirati Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Mirati Therapeutics's estimated annual revenue is currently $73.5M per year.
- Mirati Therapeutics received $130.0M in venture funding in January 2019.
- Mirati Therapeutics's estimated revenue per employee is $130,551
- Mirati Therapeutics's total funding is $2B.
- Mirati Therapeutics's current valuation is $6.9B. (January 2022)
Employee Data
- Mirati Therapeutics has 563 Employees.
- Mirati Therapeutics grew their employee count by -3% last year.
Mirati Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO and President | Reveal Email/Phone |
2 | EVP, Chief Medical Officer | Reveal Email/Phone |
3 | CSO and EVP Research | Reveal Email/Phone |
4 | Executive Director, Sales | Reveal Email/Phone |
5 | Executive Director, Sales | Reveal Email/Phone |
6 | Chief Accounting Officer (CAO) | Reveal Email/Phone |
7 | Chief Staff, Clinical Development | Reveal Email/Phone |
8 | CEO | Reveal Email/Phone |
9 | SVP | Reveal Email/Phone |
10 | Head Medical Affairs Strategy | Reveal Email/Phone |
Mirati Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Mirati Therapeutics?
Mirati Therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. Mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. The Mirati team uses a blueprint - proven by their prior work - for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. Mirati is advancing three drug candidates through clinical development for multiple oncology indications.
keywords:Biotechnology,Healthcare,Marketing,Pharmaceuticals
$2B
Total Funding
563
Number of Employees
$73.5M
Revenue (est)
-3%
Employee Growth %
$6.9B
Valuation
N/A
Accelerator
Mirati Therapeutics News
Zacks: Analysts Anticipate Mirati Therapeutics, Inc. (NASDAQ:MRTX) Will Announce Earnings of -$3.37 Per Share. Posted by admin on Apr 22nd, 2022.
Mirati Therapeutics, Inc. is a clinical-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to...
Mirati Therapeutics insiders didn't buy any shares over the last year. The chart below shows insider transactions (by companies and individuals)...
SAN DIEGO, Nov. 17, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate the Company's synthetic le ...
SAN DIEGO, Nov. 10, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company, today announced the pricing of an underwritten public offering of 3,448,275 shares of its common stock at a price to the public of $145.00 per share. The aggregate gross ...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $155.4M | 565 | 1% | N/A |
#2 | $123M | 567 | -3% | N/A |
#3 | $180M | 567 | 6% | N/A |
#4 | $101.3M | 570 | -46% | $648.1M |
#5 | $181.9M | 573 | 0% | N/A |
Mirati Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2013-10-17 | $Undisclosed | Undisclosed | Leerink Swann LLC | Article |
| 2013-10-24 | $56.9M | Undisclosed | Jefferies LLC | Article |
| 2015-09-15 | $80.0M | Undisclosed | Citigroup | Article |
| 2015-09-16 | $101.3M | Undisclosed | Citigroup | Article |
| 2017-01-09 | $65.0M | Undisclosed | Leerink Partners | Article |
| 2017-11-21 | $92.0M | Undisclosed | Cowen | Article |
| 2018-06-12 | $139.2M | Undisclosed | Cowen | Article |
| 2019-01-17 | $115.0M | Undisclosed | Multiple | Article |
| 2019-01-23 | $130.0M | Undisclosed | Multiple | Article |